公司資料
Halozyme Therapeutics, Inc. 股價、新聞與催化劑
- 股票代碼:
- HALO
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
106.94 USD (-3.13%)
收盤價
最後更新: 2026年10月1日
7.86B USD
市值
股價為何變動
截至 2026年10月1日，HALO 下跌 3.13%，收於 $106.94。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
Drug-Delivery Technology Company
Halozyme develops and licenses technologies that improve how biologic medicines are formulated and administered. Its business is based on platform access fees, development milestones, product supply, and royalties from partner medicines rather than ownership of most underlying therapeutic molecules.
ENHANZE Platform
ENHANZE uses recombinant human hyaluronidase PH20 to temporarily degrade hyaluronan in the subcutaneous space. This can enable large-volume subcutaneous delivery of therapies that would otherwise require intravenous infusion, reducing administration time and treatment burden.
Commercial Partner Products
The technology is incorporated into multiple marketed partner products, including subcutaneous formulations in oncology, immunology, and rare disease. Products such as DARZALEX SC and VYVGART Hytrulo generate recurring royalty revenue while partners retain responsibility for clinical development and commercialization.
Hypercon and High-Concentration Formulations
The Hypercon platform is designed to create highly concentrated biologic formulations that may support lower injection volumes and more flexible administration. Halozyme is pursuing multi-target collaborations to establish Hypercon as a complementary solution for medicines that cannot be optimally delivered with conventional formulations.
Expanded Injectable Technologies
Acquisitions of Antares Pharma, Elektrofi, and Surf Bio have broadened Halozyme into autoinjectors, wearable delivery systems, microparticle suspensions, and additional formulation technologies. The resulting portfolio addresses both volume and concentration constraints across subcutaneous and self-administered medicines.
未來催化劑
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
- 03
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。